Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2
- PMID: 18408886
- PMCID: PMC11131798
- DOI: 10.1007/s00018-008-8065-7
Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2
Abstract
The high-affinity Na+-dependent carnitine transporter OCTN2 (SLC22A5) has a high renal expression and reabsorbs most filtered carnitine. To gain more insight into substrate specificity of OCTN2, we overexpressed hOCTN2 in L6 cells and characterized the structural requirements of substances acting as human OCTN2 (hOCTN2) inhibitors. A 1905-bp fragment containing the hOCTN2 complete coding sequence was introduced into the pWpiresGFP vector, and L6 cells were stably transduced using a lentiviral system. The transduced L6 cells revealed increased expression of hOCTN2 on the mRNA, protein and functional levels. Structural requirements for hOCTN2 inhibition were predicted in silico and investigated in vitro. Essential structural requirements for OCTN2 inhibition include a constantly positively charged nitrogen atom and a carboxyl, nitrile or ester group connected by a 2-4-atom linker. Our cell system is suitable for studying in vitro interactions with OCTN2, which can subsequently be investigated in vivo.
Similar articles
-
Inhibition of OCTN2-mediated transport of carnitine by etoposide.Mol Cancer Ther. 2012 Apr;11(4):921-9. doi: 10.1158/1535-7163.MCT-11-0980. Epub 2012 Mar 2. Mol Cancer Ther. 2012. PMID: 22389472 Free PMC article.
-
Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.Drug Metab Pharmacokinet. 2004 Jun;19(3):180-9. doi: 10.2133/dmpk.19.180. Drug Metab Pharmacokinet. 2004. PMID: 15499185
-
Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.Am J Physiol Renal Physiol. 2000 Sep;279(3):F584-91. doi: 10.1152/ajprenal.2000.279.3.F584. Am J Physiol Renal Physiol. 2000. PMID: 10966938
-
Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).Expert Opin Ther Targets. 2018 Aug;22(8):715-726. doi: 10.1080/14728222.2018.1502273. Epub 2018 Jul 23. Expert Opin Ther Targets. 2018. PMID: 30016594 Review.
-
Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21).Biopharm Drug Dispos. 2013 Jan;34(1):29-44. doi: 10.1002/bdd.1816. Epub 2012 Oct 14. Biopharm Drug Dispos. 2013. PMID: 22952014 Review.
Cited by
-
Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies.FASEB J. 2020 Dec;34(12):15734-15752. doi: 10.1096/fj.202001497R. Epub 2020 Oct 30. FASEB J. 2020. PMID: 33124720 Free PMC article.
-
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter.Mol Pharm. 2010 Dec 6;7(6):2120-31. doi: 10.1021/mp100226q. Epub 2010 Sep 29. Mol Pharm. 2010. PMID: 20831193 Free PMC article.
-
SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.Molecules. 2019 Dec 19;25(1):14. doi: 10.3390/molecules25010014. Molecules. 2019. PMID: 31861504 Free PMC article. Review.
-
High affinity carnitine transporters from OCTN family in neural cells.Neurochem Res. 2010 May;35(5):743-8. doi: 10.1007/s11064-010-0131-5. Epub 2010 Feb 9. Neurochem Res. 2010. PMID: 20143157
-
A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.Mol Pharm. 2012 Apr 2;9(4):905-13. doi: 10.1021/mp200438v. Epub 2012 Feb 28. Mol Pharm. 2012. PMID: 22339151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources